Macciardi
Fabio Macciardi, Paris FR
Patent application number | Description | Published |
---|---|---|
20080254451 | Compositions and Methods for Treating Schizophrenia and Related Disorders - The present invention relates, generally, to methods and compositions for detecting or treating mental disorders, such as schizophrenia. The present invention more particularly discloses the identification of human genes which can be used for the diagnosis, prevention and treatment of schizophrenia and related disorders, as well as for the screening of therapeutically active drugs. The invention further discloses specific polymorphisms or alleles of the CNTFR gene that are related to schizophrenia, as well as diagnostic tools and kits based on these markers. The invention can be used in the diagnosis of or predisposition to, detection, prevention and/or treatment of schizophrenia and related disorders. | 10-16-2008 |
20090136450 | THERAPY FOR NEUROLOGICAL DISEASES - The present invention relates to compositions and methods for treating neurological diseases in a subject. More specifically, the invention relates to combination therapies for treating such diseases, using a c-kit inhibitor and a neuroactive compound. The invention may be used against a variety of demyelinating diseases, including multiple sclerosis, in any mammalian subject, particularly human subjects, and at various stages of disease progression. | 05-28-2009 |
Fabio Macciardi, Milano IT
Patent application number | Description | Published |
---|---|---|
20080241839 | Method for correlating differential brain images and genotypes; genes that correlate with differential brain images - Methods of assigning quantitative phenotype measurement summary statistics to differential brain image information associated with neuropsychiatric disorders are provided. Summary statistics are correlated to genotype information to identify loci that correlate with differential brain image phenotypes. Methods of identifying modulators of genes at the loci are provided, as well as modulators identified by the methods. Systems for correlating polymorphisms and differential brain image phenotypes, for identifying modulators and for making correlations between differential brain activation phenotypes and genotypes are also provided | 10-02-2008 |
20130018024 | METHODS AND SYSTEMS FOR PHARMACOGENOMIC TREATMENT OF CARDIOVASCULAR CONDITIONS - Methods and systems are provided herein that are based on the effects of genetic variations on the biological activities associated to rostafuroxin in an individual. In particular, compositions, methods and systems are herein described that are based on an indentified influence on an individual response to rostafuroxin of one or more polymorphisms in an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, and/or a genetic variation in linkage disequilibrium therewith. | 01-17-2013 |
Fabio Macciardi, Irvine, CA US
Patent application number | Description | Published |
---|---|---|
20130123189 | DETERMINATION OF SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT RESPONSE FOR GLATIRAMER ACETATE - This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: | 05-16-2013 |
20150045306 | DETERMINATION OF SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT RESPONSE FOR GLATIRAMER ACETATE - This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate. | 02-12-2015 |